Hadassah

Complex, Less Debilitating Treatment for Neuroendocrine Cancer Now Available in Israel at Hadassah

Wednesday, Feb 15 2012

A treatment for neuroendocrine cancer that was previously only available abroad is now being provided at the Hadassah University Medical Center. Patients are injected with radioactive material that attaches to the malignant cell, absorbing and destroying it with minimal damage to other tissue. The new treatment is the outgrowth of three years of collaboration between Hadassah and Israel's Soreq Nuclear Research Center, an applied research and development institute affiliated with the Israel Atomic Energy Commission. The radioactive material is assembled at the Soreq Center and sent to Hadassah once a week at a set time.

Based on the fact that these endocrine tumors have an increased ability to absorb a hormone called somatostatin, the therapeutic procedure involves attaching a similar molecule to the hormone which is, in turn, attached to a radioactive atom. The atom binds to receptors on the outer membrane of the tumor and is absorbed into the malignant cell, emitting ionizing radiation which destroys it.

According to Dr. Asher Salmon, Senior Oncologist at Hadassah's Sharett Institute of Oncology, the treatment successfully prolongs life expectancy for 80 percent of patients and retards the progress of the disease for 50 percent. "This treatment, considered one of the best and most innovative available, differs from chemotherapy, providing prolonged relief for the patients with only a few side effects," he says. Following just one day in the hospital, patients are sent home; within several days, they can resume their normal lives.

Hadassah's departments of endocrinology, oncology, nuclear medicine, and radiology collaborate in providing this treatment to Hadassah's patients.

Comments

No comments yet.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Wednesday, Jun 20 2018

First in Israel: Hadassah Uses Innovative Technology to Treat Cancer in Spine

A multidisciplinary team at Hadassah Hospital Ein Kerem recently employed an innovative technology to treat cancer metastases near the spinal cord--a first for Israel.

READ MORE ›
alt_text

Tuesday, Jun 19 2018

American Journal of Ophthalmology Article Celebrates the Centennial of Hadassah Ophthalmology

The centennial anniversary of the Hadassah Medical Organization's Department of Ophthalmology is celebrated in the May issue of the American Journal of Ophthalmology, with an article by the immediate past director, Prof. Jacob Pe'er, and the current director, Prof. Itay Chowers.

READ MORE ›

Tuesday, Jun 12 2018

Hadassah Ophthalmology Department Research Highlighted by JAMA

Thanking the Hadassah Medical Organization’s researchers for their ”excellent submission” to JAMA Ophthalmology regarding a multi-center international study of the variable effectiveness of treatment for neovascular age-related macular degeneration (nAMD), the editors explained that their article was one of just a few from 12 JAMA on-line journals to be highlighted in The JAMA Network Reader this weekend.

READ MORE ›
alt_text

Monday, Jun 11 2018

Ruth Radiano: Passionate New Director of Nursing at Hadassah Hospital Mount Scopus

Translating her passion and professionalism into action, Ruth Radiano, the new Director of Nursing at Hadassah Hospital Mount Scopus, brings a background of 26 years of nursing at Hadassah.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More